Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Qingsheng Xu (17078830) (author)
Outros Autores:	Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Publicado em:	2025
Assuntos:	Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Por: Qingsheng Xu (17078830)
Publicado em: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Por: Sied Kebir (15048732)
Publicado em: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Por: Sied Kebir (15048732)
Publicado em: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Por: Sied Kebir (15048732)
Publicado em: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Por: Sied Kebir (15048732)
Publicado em: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Por: Sied Kebir (15048732)
Publicado em: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Por: Tobias Kessler (17079209)
Publicado em: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Por: William Kelly (15439117)
Publicado em: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Por: William Kelly (15439117)
Publicado em: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Por: Dwight H. Owen (15034782)
Publicado em: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Por: Tom Wei-Wu Chen (15053003)
Publicado em: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Por: Tom Wei-Wu Chen (15053003)
Publicado em: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Por: Tom Wei-Wu Chen (15053003)
Publicado em: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Por: Tom Wei-Wu Chen (15053003)
Publicado em: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Por: Tom Wei-Wu Chen (15053003)
Publicado em: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Por: James S. Wilmott (15008931)
Publicado em: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Por: James S. Wilmott (15008931)
Publicado em: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Por: John A. Ligon (15024477)
Publicado em: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Por: Giuseppe Basile (15051269)
Publicado em: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Por: Andrés Elía (15055031)
Publicado em: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Por: Andrés Elía (15055031)
Publicado em: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Por: Andrés Elía (15055031)
Publicado em: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Por: Andrés Elía (15055031)
Publicado em: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Por: Andrés Elía (15055031)
Publicado em: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
Por: Roger Li (17078665)
Publicado em: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Por: Ulka N. Vaishampayan (15051039)
Publicado em: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Por: Ulka N. Vaishampayan (15051039)
Publicado em: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Por: Ulka N. Vaishampayan (15051039)
Publicado em: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Por: Ulka N. Vaishampayan (15051039)
Publicado em: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Por: Nigel Bundred (15046233)
Publicado em: (2025)

Cannot write session to /tmp/vufind_sessions/sess_76rvr6hjjq4r46suoj3btrtl41